Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Aaron Ellenbogen
Symptoms in early Parkinson’s disease improve with tavapadon
Key takeaways: Dopamine agonists target D2/D3 receptors, possibly increasing adverse events. Tavapadon targets D1/D5 receptors, reducing adverse event risks. Patient Global Impression of Change response improved with treatment. Motor function improved with a favorable safety profile for patients in the early stages of Parkinson’s disease using tavapadon, according to a study published in JAMA Neurology.
LRRK2 -targeting antisense oligonucleotide in Parkinson’s disease: a phase 1 randomized controlled trial
|
Abstract LRRK2 (encoding leucine-rich repeat kinase 2) variants are the most common genetic cause of Parkinson’s disease (PD). Lowering LRRK2 levels and/or inhibiting LRRK2 activity may modify PD-associated neuropathology. BIIB094 (ION859), an antisense oligonucleotide, targets LRRK2 mRNA for degradation. REASON was a first-in-human randomized phase 1 study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intrathecal BIIB094 in patients with PD.
By Omar S. Mabrouk, Ben Tichler, Eva Thoma, Sara Alexanian, Jingxian Chen, Tzu-Ying Liu, John Annand, Unnati Kapadnis, Kyle Ferber, Yuka Moroishi, Julie M Czerkowicz, Jennifer A. Inra, Ronald B. Postuma, Tanya Gurevich, Pablo Mir, Huw Morris, Jason Aldred, Matthew Brodsky, Aaron Ellenbogen, Christopher M Tolleson, Andrew Siderowf, Charalampos Tzoulis, María Martí, Hien T. Zhao, Holly B. Kordasiewicz, Roger M Lane, Warren D. Hirst, Stephanie Fradette, Danielle Graham, H. Moore Arnold, Beth Hirschhorn, Roy Llorens Arenas, Alan A. Shomo, Kelly E. Glajch, Danielle Larson, Ernest Balaguer
|
Nature
Verified
Efficacy Remaining at Time of Requested Re-Treatment for Cervical Dystonia: A Potential New Treatment Paradigm with DaxibotulinumtoxinA
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
IPX203 vs Immediate-Release Carbidopa-Levodopa for the Treatment of Motor Fluctuations in Parkinson Disease
Key Points Question Can extended-release carbidopa-levodopa (IPX203) improve symptomatic control in patients with Parkinson disease who are experiencing motor fluctuations while taking immediate-release carbidopa-levodopa?
Pharmacokinetics of Inhaled Levodopa Administered With Oral Carbidopa in the Fed State in Patients With Parkinson's Disease
Highlights • CVT-301 is an inhaled levodopa treatment for OFF periods in Parkinson's disease. • Pharmacokinetics of CVT-301 and oral ingested carbidopa/levodopa were examined. • Levodopa from CVT-301 was more rapidly absorbed than from oral carbidopa/levodopa. • CVT-301 produced lower interpatient levodopa variability than oral carbidopa/levodopa. • Findings support inhaled levodopa for adjunctive treatment of OFF periods.
Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 - Brys - - Movement Disorders - Wiley Online Library
Research Article Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054 Miroslaw Brys MD, PhD Corresponding Author E-mail address: mirek.brys@biogen.com https://orcid.org/0000-0003-3682-117X Biogen, Cambridge, Massachusetts, USA Correspondence to: Dr. Miroslaw Brys, 300 Binney Street, 5th floor, Cambridge, MA 02142; E‐mail: mirek.brys@biogen.com Search for more papers by this author Funding agency: The study was funded by Biogen.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Aaron
Contact Aaron, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack